Clinical Trials Browser

Lymphoma, Follicular × polatuzumab vedotin × 1 year × Clear all

NCT05169658 2026-05-13

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Phase 2 Completed

42 enrolled 10 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT04491370 2026-04-15

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Phase 1/2 Recruiting

20 enrolled

Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05410418 2025-12-15

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Phase 2 Active not recruiting

34 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell

NCT06453044 2025-09-24

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Phase 2 Recruiting

41 enrolled

Lymphoid

Lymphoma, Follicular